Research programme: anti-CD40L and anti-CD40 agents - Bristol-Myers Squibb

Drug Profile

Research programme: anti-CD40L and anti-CD40 agents - Bristol-Myers Squibb

Alternative Names: Anti-5c8 - Bristol-Myers Squibb; Anti-CD40L antibody - BMS; Anti-gp39 - Bristol-Myers Squibb; Anti-gp39 monoclonal antibody - Bristol-Myers Squibb; Anti-gp39 monoclonal antibody MR1; Anti-T-BAM - Bristol-Myers Squibb; Anti-TRAP - Bristol-Myers Squibb; BMS-202448; MR1

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors; CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Immunological disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in USA (Parenteral)
  • 30 Jun 2012 Preclinical trials in Immunological disorders (Anti-CD40) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top